Logo
Login
$REGN
$807.84 +$2.82 (0.35%) Live

Company Executives

$REGN Management Team

Dr. Andrew Murphy

Executive Vice President - Research

Age 67
Compensation $8.363M USD
Sex Male

Dr. Leonard Schleifer

Co-Chairman of the Board

President

Chief Executive Officer

Founder

Age 72
Compensation $6.823M USD
Sex Male

Dr. George Yancopoulos

Co-Chairman of the Board

President

Chief Scientific Officer

Age 65
Compensation $6.797M USD
Sex Male

Mr. Christopher Fenimore

Chief Financial Officer

Executive Vice President - Finance

Age 54
Compensation $6.268M USD
Sex Male

Mr. Daniel Van Plew

Executive Vice President

General Manager - Industrial Operations and Product Supply

Age 52
Compensation $8.655M USD
Sex Male

Ms. Marion McCourt

Executive Vice President - Commercial

Age 65
Compensation $6.900M USD
Sex Female

Mr. Jason Pitofsky

Vice President

Controller

Age 48
Compensation -
Sex Male

Mr. Joseph LaRosa

Executive Vice President

General Counsel

Secretary

Age 66
Compensation $7.127M USD
Sex Male

Board of Directors

From the proxy statement filed Apr 24, 2026
Directors
13
serving now
Independent
11 of 11
stated in the proxy; 2 not stated
Average tenure
19.2 years
from year joined
CEO also chairs the board
Yes
Leonard S. Schleifer, M.D., Ph.D. and George D. Yancopoulos, M.D., Ph.D.
Director Age On board Independent Committees Other public boards Pay Source
Joseph L. Goldstein, M.D.
85 1991
35 years
 Independent
Technology Committee
None stated Not stated
Christine A. Poon
Lead independent director
 73 2010
16 years
 Independent None stated Neurocrine Biosciences, Inc., Prudential Financial, Inc. Not stated
David P. Schenkein, M.D.
68 2023
3 years
 Independent
Compensation Committee Technology Committee
Denali Therapeutics Inc., Prime Medicine, Inc. Not stated
Craig B. Thompson, M.D.
73 2022
4 years
 Independent
Technology Committee
Charles River Laboratories International, Inc. Not stated
Huda Y. Zoghbi, M.D.
71 2016
10 years
 Independent
Compensation Committee Technology Committee
None stated Not stated
N. Anthony Coles, M.D.
65 2017
9 years
 Independent
Audit Committee Compensation Committee
None stated Not stated
Kathryn Guarini, Ph.D.
54 2023
3 years
 Independent
Audit Committee
None stated Not stated
Arthur F. Ryan
83 2003
23 years
 Independent
Audit Committee
None stated Not stated
George L. Sing
76 1988
38 years
 Independent
Audit Committee · Chair Compensation Committee
None stated Not stated
Bonnie L. Bassler, Ph.D.
63 2016
10 years
 Independent
Technology Committee
Royalty Pharma plc Not stated
Michael S. Brown, M.D.
85 1991
35 years
 Independent None stated None stated Not stated
Leonard S. Schleifer, M.D., Ph.D.
Board chair, CEO
 73 1988
38 years
 Not stated
Technology Committee
None stated Paid as CEO
George D. Yancopoulos, M.D., Ph.D.
Board chair, Executive officer
 66 2001
25 years
 Not stated
Technology Committee
None stated Not stated

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

Related-party transactions

1 disclosed in the proxy filed Apr 24, 2026
Dr. Schleifer
Amount not stated
2025 and 2026 to date

Company conducted a pre-clinical research project at Dr. Schleifer's request; foundation made or is expected to make payments representing the estimated fully burdened cost of the project

With a foundation established by Dr. Schleifer Open in proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support
View Pricing Plans